¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Host Cell Factor C1"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
¿µ¹® host ÇÑ±Û ¼÷ÁÖ
¼³¸í   
  ´Ù¸¥ »ý¹°(±â»ýü)À» ±â»ý½ÃÄÑ, ¿µ¾çÀ» °ø±ÞÇϴ µ¿¹° ¶Ç´Â ½Ä¹°. ¸¶Áö¸·ÀÇ ¼öÁÖ¸¦ Á¾¼÷ÁÖ, ¹ßÀ°ÀÇ µµÁß¿¡ ±â»ýÇϴ ¼÷ÁÖ¸¦ Áß°£ ¼÷ÁÖ¶ó°í ÇÑ´Ù. ±â»ýµ¿¹° Áß¿¡´Â ¼÷ÁÖ°¡ Æ¯Á¤ÇÑ Á¾ÀÏ ¶§µµ ÀÖ°í ¶Ç ¸¹Àº ±â»ýÃæ°ú °°À̱נ¹ß»ý´Ü°è¿¡ µû¶ó ¸¹Àº Á¾·ùÀÇ ¼÷ÁÖ¸¦ ÇÊ¿ä·Î Çϴ °Íµµ ÀÖ´Ù. ÀÌ °æ¿ì ¾Ö¹ú·¹°¡ ±â»ýÇϴ ¼÷ÁÖ¸¦ Áß°£¼÷ÁÖ, ¼ºÃ¼°¡ ±â»ýÇϴ ¼÷ÁÖ¸¦ ÃÖÁ¾¼÷ÁÖ¶ó°í ÇÑ´Ù. °£ÁúÀΠ°æ¿ì¿¡´Â ¹°°íµ¿ÀÌ Áß°£¼÷ÁÖÀ̰í, ¼Ò-¾ç µîÀº ÃÖÁ¾¼÷ÁÖ°¡ µÈ´Ù. ±â»ý½Ä¹°¿¡´Â °Ü¿ì»ìÀ̿͠°°ÀÌ Á¹Âü³ª¹« µîÀ» ¼÷ÁַΠÇÏ¿© ½º½º·Î ±¤ÇÕ¼ºÀ» Çϸ鼭µµ ¼÷ÁÖ¿¡°Ô¼­ ¿µ¾çÀ» ¾ò´Â °Í°ú, ¾ß°í¿Í °°ÀÌ »ý°­ µîÀÇ »Ñ¸®¸¦ ¼÷ÁַΠÇÏ¿© ¼÷ÁÖ¿¡°Ô¼­¸¸ ¿µ¾çÀ» ÀÇÁ¸Çϴ °ÍÀÌ ÀÖ´Ù. ±â»ý»ý¹°¿¡´Â ÀÌ ¹Û¿¡µµ »ý¹°ÀÇ »çü³ª ±× ºÐÇØÁß¿¡ Àִ °Í, ¹èÃâ¹° µîÀ» ¼÷ÁַΠÇϴ °Íµµ ÀÖ´Ù.
¿µ¹® graft versus host reaction ÇÑ±Û ÀÌ½ÄÆí´ë ¼÷ÁÖ¹ÝÀÀ
¼³¸í   
  ¸é¿ªÀ̶õ ÀÚ½ÅÀÇ °Í°ú ÀÚ½ÅÀÇ °ÍÀÌ ¾Æ´Ñ °ÍÀ» ±¸ºÐÇØ¼­ ÀÚ½ÅÀÇ °ÍÀÌ ¾Æ´Ñ °ÍÀ» °ø°ÝÇÏ¿© »ý¹°ÇÐÀû È°¼ºÀ» ¾ø¾Ö°Å³ª Á¦°ÅÇϴ °ÍÀÌ´Ù. ÀÌ ¸é¿ªÀº ÁַΠÇ÷¾×¿¡ Àִ ¼¼Æ÷¿¡ ÀÇÇØ¼­ ÀÌ·ç¾îÁø´Ù. Æ¯È÷ ¸²ÇÁ±¸´Â ÀÌ ¸é¿ª¿¡ ÁßÃßÀûÀΠ¿ªÇÒÀ» Çϴ ¼¼Æ÷ÀÌ´Ù. ÀÌ½ÄÆí´ë¼÷ÁÖ¹ÝÀÀÀ̶ó´Â °ÍÀº À̽ĵǾî¿Â Á¶Á÷¿¡ Á¸ÀçÇϴ ŸÀÎÀÇ Ç÷±¸µéÀÌ ¼÷ÁÖÀÇ ¼¼Æ÷¸¦ °ø°ÝÇϴ °ÍÀ» ¸»ÇÑ´Ù. Áï À̽ĵǾî¿Â Á¶Á÷°ú ÇÔ²² µé¾î¿Â Ç÷±¸µéÀÌ À̽ÄÀ» ¹ÞÀº »ç¶÷ÀÇ ¼¼Æ÷¸¦ Å¸ÀÎÀÇ °ÍÀ¸·Î ÀÎÁöÇØ¼­ °ø°ÝÇϴ Çö»óÀÌ´Ù. À̰ÍÀº À̽ÄÀ» ¹ÞÀº »ç¶÷ÀÇ ¸é¿ª»óŰ¡ Á¤»óÀûÀÏ °æ¿ì¿¡´Â ÀϾÁö ¾Ê´Âµ¥ ¿Ö³ÄÇϸ頸鿪»óŰ¡ Á¤»óÀÏ °æ¿ì¿¡´Â À̽ĵǾî¿Â Àå±â¿Í ´õºÒ¾î µé¾î¿Â Å¸ÀÎÀÇ Ç÷±¸µéÀ» À̽ÄÀ» ¹ÞÀº »ç¶÷ÀÇ Ç÷±¸°¡ Å¸ÀÎÀÇ °ÍÀ¸·Î ÀÎÁöÇØ¼­ °ø°ÝÀ» ÇÏ°í ¼ýÀûÀ¸·Î À¯¸®ÇÏ¿© ¸ðµÎ Á×ÀÏ ¼ö°¡ Àֱ⠶§¹®ÀÌ´Ù.
¿µ¹® rheumatoid factor ÇÑ±Û ·ù¸¶Æ¼½º ÀÎÀÚ
¼³¸í   
  IgGÀÇ FcºÎÀ§¿¡ Àִ Ç׿ø°áÁ¤ÀÎÀÚ¿¡ ´ëÇÑ Ç×ü·Î¼­ ÀüÇüÀûÀΠ¶Ç´Â È®½ÇÇÑ ·ù¸¶Æ¼½º°üÀý¿°(rheumatoid arthritis) È¯ÀÚÀÇ 80%¿¡¼­ ¹ß°ßµÈ´Ù. ·ù¸¶Æ¼½º ÀÎÀڴ IgM, IgG, IgAÁß Çϳª°¡ µÉ ¼ö ÀÖÀ¸³ª ÁַΠIgMÀÌ´Ù. ¼Ò¾Æ·ù¸¶Æ¼½º°üÀý¿°(juvenile rheumatoid arthritis: ¼Ò¾Æ±â¿¡ ¹ß»ýÇϴ ·ù¸¶Æ¼½º°üÀý¿°)À» ºñ·ÔÇÑ, ´Ù¸¥ °áÇÕÁ¶Á÷º´À̳ª °¨¿°º´¿¡µµ ³ªÅ¸³¯ ¼ö ÀÖ´Ù
¿µ¹® growth factor ÇÑ±Û ¼ºÀåÀÎÀÚ
¼³¸í   
  ¼¼Æ÷ÀÇ ºÐÈ­ ¹× ¼ºÀå¿¡ °ü¿©Çϴ ´Ü¹éÁú. ¼ºÀåÀÎÀڴ Á¤»ó ¼¼Æ÷Áֱ⿡ ÇʼöÀûÀ̱⠶§¹®¿¡ µ¿¹°ÀÇ »ý¸í¿¡ Áß´ëÇÑ ¿ä¼Ò°¡ µÈ´Ù. ¹«¾ùº¸´Ùµµ ¼ºÀåÀÎÀڴ Å¾ÆÀÇ ¹ßÀ°À» Á¶Á¤Çϰí Á¶Á÷ÀÇ À¯Áö ¹× º¸¼ö¿¡ Áß´ëÇÑ ¿ªÇÒÀ» Çϸç, Ç÷±¸ÀÇ »ý¼ºÀ» ÀÚ±ØÇÑ´Ù. ¶ÇÇÑ ¾ÏÀÇ ÁøÇà°úÁ¤¿¡µµ °ü¿©ÇÑ´Ù.
¿µ¹® risk factor ÇÑ±Û À§ÇèÀÎÀÚ
¼³¸í   
  ±¹Á¦¹æ»ç¼±¹æÈ£À§¿øÈ¸(ICRP)°¡ 1977³â ±Ç°í¿¡¼­ ¹æ»ç¼±¹æÈ£ÀÇ ¸ñÀûÀ¸·Î Ã¤ÅÃÇÑ Áö¼ö·Î, ´ÜÀ§¼±·®(1 Sv)´ç È®·üÀû ¿µÇâÀÇ ¹ß»ýÈ®·üÀ» ÃßÁ¤ÇÏ¿© ³ªÅ¸³½ °ÍÀÌ´Ù. »ý½Ä¼± ¼±·®¿¡ ´ëÇÑ À¯ÀüÀû¿µÇâÀÇ ¹ß»ý·ü(4¡¿10£­3/Sv)À̳ª Àû»ö°ñ¼ö¼±·®¿¡ ´ëÇÑ ¹éÇ÷º´ ¹ß»ý·ü(2¡¿10£­3/Sv)µî ¿Ü¿¡ »À, ÇãÆÄ, °©»ó»ù, Á¥»ù, ±âŸ Á¶Á÷ÀÇ À§ÇèÁö¼ö¸¦ ÃøÁ¤ÇÏ¿©, È®·üÀû ¿µÇâÀÇ Àü½Å¿¡ À־ Ä¡»çÀ§ÇèÁö¼öÀÇ Çհ踦 16.5¡¿10£­3/Sv·Î ÇÏ¿´´Ù. ±×ÈÄ ICRP´Â 1990³â ±Ç°í¿¡¼­ ´ë»óÀÌ µÇ´Â Á¶Á÷°ú Àå±â¸¦ Ãß°¡Çϰí, ¼öÄ¡ °³Á¤À» Çϸ鼭 ¸íεµ °¢¸ñÀûÈ®·üÁö¼ö¶ó°íÇÏ¿´´Ù. ÀÌ ±Ç°í¿¡ ÀÇÇϸé, Ä¡»çÀû È®·üÀû ¿µÇâÀÇ È®·üÁö¼öÀÇ ÇÕ°è´Â, ÀϹÝÀο¡ ÀÖ¾î 60.0¡¿10£­3/SvÀÌ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • host integration factor
    ¼÷ÁÖÅëÇÕÀÎÀÚ
  • accidental host
    ¿ì¿¬¼÷ÁÖ
  • definitive host
    Á¾¼÷ÁÖ
  • final host
    Á¾¼÷ÁÖ
  • graft versus host reaction
    ÀÌ½ÄÆí´ë¼÷ÁÖ¹ÝÀÀ
  • graft-versus-host disease
    ÀÌ½ÄÆí´ë¼÷ÁÖº´
  • host
    ¼÷ÁÖ
  • host adaptation
    ¼÷ÁÖÀûÀÀ
  • host attribute
    ¼÷ÁÖ¼Ó¼º
  • host defense
    ¼÷ÁÖ¹æ¾î
  • host preference
    ¼÷ÁÖ¼±È£
  • host range
    ¼÷ÁÖ¹üÀ§
  • host selection
    ¼÷ÁÖ¼±ÅÃ
  • host specificity
    ¼÷ÁÖÆ¯À̼º
  • host susceptibility
    ¼÷ÁÖ°¨¼ö¼º
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • host defense
    ¼÷ÁÖ¹æ¾î
  • host
    ¼÷ÁÖ
  • definitive host
    Á¾¼÷ÁÖ
  • intermediate host
    Áß°£¼÷ÁÖ
  • reservoir host
    º¸À¯¼÷ÁÖ
  • graft versus host reaction
    ÀÌ½ÄÆí´ë¼÷ÁÖ¹ÝÀÀ
  • factor
    ÀÎÀÚ, ¿äÀÎ, °è¼ö
  • activation factor
    Ȱ¼ºÀÎÀÚ
  • antiplatelet factor
    Ç×Ç÷¼ÒÆÇÀÎÀÚ
  • coagulation V factor
    Á¦5Ç÷¾×ÀÀ°íÀÎÀÚ
  • exclusion of confounding factor
    ±³¶õº¯¼ö¹èÁ¦
  • growth factor
    ¼ºÀåÀÎÀÚ
  • intrinsic factor
    ³»ÀÎÀÎÀÚ, ³»ÀÎÀÚ
  • nerve growth factor
    ½Å°æ¼ºÀåÀÎÀÚ
  • platelet activating factor
    Ç÷¼ÒÆÇȰ¼ºÀÎÀÚ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • host integration factor
    ¼÷ÁÖÅëÇÕÀÎÀÚ
  • abnormal host
    ºñÁ¤»ó¼÷ÁÖ
  • accidental host
    ¿ì¿¬¼÷ÁÖ
  • alternate host
    ±³´ë¼÷ÁÖ
  • amplifier host
    ÁõÆø¼÷ÁÖ
  • host adaptation
    ¼÷ÁÖÀûÀÀ
  • host attribute
    ¼÷ÁÖ¼Ó¼º
  • compromised host
    ŸÇù¼÷ÁÖ
  • crustacean host
    °©°¢·ù¼÷ÁÖ
  • definitive host
    ÃÖÁ¾¼÷ÁÖ
  • graft-versus-host disease
    À̽Ĵë¼÷ÁÖº´
  • host defense
    ¼÷ÁÖ¹æ¾î
  • final host
    (¢¡definitive host) ÃÖÁ¾¼÷ÁÖ
  • graft versus host reaction
    ÀÌ½ÄÆí´ë¼÷ÁÖ¹ÝÀÀ
  • host
    ¼÷ÁÖ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • graft versus host disease
    ´ë¼÷ÁÖÀÌ½ÄÆíÁúȯ
  • graft versus host disease
    ÀÌ½ÄÆí´ë¼÷ÁÖº´.
  • graft versus host disease
    ÀÌ½ÄÆí´ë¼÷ÁÖº´
  • graft versus host reaction
    ÀÌ½ÄÆí´ë¼÷ÁÖ¹ÝÀÀ(ì¹ãÕø¸ÓßâÖñ«Úãëë).
  • graft versus host reaction (GVHR)
    ´ë¼÷ÁÖÀÌ½ÄÆí¹ÝÀÀ
  • graft-versus-host disease
    ÀÌ½ÄÆí´ë¼÷ÁÖº´
  • graft-versus-host disease
    ÀÌ½ÄÆí´ë ¼÷ÁÖº´
  • host
    ¼÷ÁÖ
  • host
    ¼÷ÁÖ
  • host adaptation
    ¼÷ÁÖÀûÀÀ.
  • pneumonia,in immunocompromised host
    ¸é¿ª±â´ÉÀúÇϼ÷ÁÖÀÇ (Øóæ¹Ñ¦Òöî¸ù»âÖñ«¡­)
  • relation[ship], host-parasite
    ¼÷ÁÖ-±â»ýü »óÈ£°ü°è
  • F factor (fertility factor)
    FÀÎÀÚ, ¼öÅÂÀÎÀÚ
  • B cell differentiation factor (BCDF)
    B¼¼Æ÷ ºÐÈ­À¯¹ßÀÎÀÚ
  • B cell growth factor
    B ¼¼Æ÷¼ºÀåÀÎÀÚ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • host factor
    ¼÷ÁÖÀÎÀÚ
  • host integration factor (HIF)
    ¼÷ÁÖÅëÇÕÀÎÀÚ
  • compromised host
    ÀúÇ×·Â ÀúÇϼ÷ÁÖ
  • definitive host =final h.
    ÃÖÁ¾¼÷ÁÖ(¡­âÖñ«).
  • final host
    ÃÖÁ¾¼÷ÁÖ, Á¾¼÷ÁÖ
  • graft versus host disease
    ÀÌ½ÄÆí´ë¼÷ÁÖº´
  • graft versus host disease
    ÀÌ½ÄÆí´ë¼÷ÁÖº´.
  • graft versus host disease
    ´ë¼÷ÁÖÀÌ½ÄÆíÁúȯ
  • graft versus host reaction
    ÀÌ½ÄÆí´ë¼÷ÁÖ¹ÝÀÀ(ì¹ãÕø¸ÓßâÖñ«Úãëë).
  • graft versus host reaction (GVHR)
    ´ë¼÷ÁÖÀÌ½ÄÆí¹ÝÀÀ
  • graft-versus-host disease
    ÀÌ½ÄÆí´ë¼÷ÁÖº´
  • graft-versus-host disease
    ÀÌ½ÄÆí´ë ¼÷ÁÖº´
  • host
    ¼÷ÁÖ
  • host
    ¼÷ÁÖ
  • host adaptation
    ¼÷ÁÖÀûÀÀ.
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Host
    ¼÷ÁÖ
    [¿¾ ¿ë¾î] ¼÷ÁÖ
  • Chief cell [Type I glomus cell]
    °ú¸³¼¼Æ÷
    [¿¾ ¿ë¾î] ÁÖ¼¼Æ÷(Á¦1Çü»ç±¸¼¼Æ÷)
  • Clear cell [Epinephrine cell]
    ¹àÀº¼¼Æ÷ [¿¡Çdz×ÇÁ¸°¼¼Æ÷]
    [¿¾ ¿ë¾î] ¸í¼¼Æ÷(¿¡Çdz×ÇÁ¸°ºÐºñ¼¼Æ÷)
  • Sustentacular cell [Sertoli cell]
    ¹öÆÀ¼¼Æ÷
    [¿¾ ¿ë¾î] ÁöÁÖ¼¼Æ÷
  • Beta cell [Insulin cell]
    º£Å¸¼¼Æ÷ [Àν´¸°¼¼Æ÷]
    [¿¾ ¿ë¾î] º£Å¸¼¼Æ÷
  • Secretory epithelial cell [Glandular cell]
    ºÐºñ»óÇǼ¼Æ÷ [»ù¼¼Æ÷]
    [¿¾ ¿ë¾î] ºÐºñ»óÇǼ¼Æ÷
  • Interstitial cell [Dark cell]
    »çÀÌÁú¼¼Æ÷
    [¿¾ ¿ë¾î] °£Áú¼¼Æ÷
  • Interstitial cell [Leydig`s cell]
    »çÀÌÁú¼¼Æ÷
    [¿¾ ¿ë¾î] °£Áú¼¼Æ÷
  • Bronchiolar cell [Clara cell]
    ¼¼±â°üÁö¼¼Æ÷
    [¿¾ ¿ë¾î] ºÐºñ¼¼Æ÷
  • Parafollicular cell [Calcitonin cell]
    ¼ÒÆ÷°ç¼¼Æ÷
    [¿¾ ¿ë¾î] ¼ÒÆ÷¹æ¼¼Æ÷
  • Neurolemmal cell [Schwann`s cell]
    ½Å°æÁý¼¼Æ÷
    [¿¾ ¿ë¾î] ½Å°æÃʼ¼Æ÷
  • Alpha cell [Glucagon cell]
    ¾ËÆÄ¼¼Æ÷ [±Û·çÄ«°ï¼¼Æ÷]
    [¿¾ ¿ë¾î] ¾ËÆÄ¼¼Æ÷
  • Dark cell [Norepinephrine cell]
    ¾îµÎ¿î¼¼Æ÷ [³ë¸£¿¡Çdz×ÇÁ¸°¼¼Æ÷]
    [¿¾ ¿ë¾î] ¾Ï¼¼Æ÷(³ë¸£¿¡Çdz×ÇÁ¸°ºÐºñ¼¼Æ÷)
  • Chief cell [Type I glomus cell]
    °ú¸³¼¼Æ÷
    [¿¾ ¿ë¾î] ÁÖ¼¼Æ÷
  • Supporting cell [Sertoli cell]
    ¹öÆÀ¼¼Æ÷
    [¿¾ ¿ë¾î] ÁöÁÖ¼¼Æ÷
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Duffy factor
    ´õÇÇÀÎÀÚ
  • excretory cell
    ¹è¼³¼¼Æ÷
  • flame cell
    ºÒ²É¼¼Æ÷
  • G cell G
    ¼¼Æ÷
  • germ cell
    ¹è¼¼Æ÷
  • interstitial plasma cell pneumonia
    °£Áú¼ºÇüÁú¼¼Æ÷Æó¿°
  • nurse cell
    º¸¸ð¼¼Æ÷
  • renette cell
    ¹è¼³¼¼Æ÷
  • tegumental cell
    Ç¥ÇǼ¼Æ÷
  • vitelline cell
    ³­È²¼¼Æ÷
  • accidental host
    ¿ì¿¬¼÷ÁÖ
  • alternate host
    ±³´ë¼÷ÁÖ
  • amplifier host
    ÁõÆø¼÷ÁÖ
  • crustacean host
    °©°¢·ù¼÷ÁÖ
  • definitive host
    Á¾¼÷ÁÖ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • host-cell reactivation
    ¼÷ÁÖ ¼¼Æ÷ ÀçȰ¼ºÈ­(âÖñ«á¬øàî¢üÀàõûù)
  • integration host factor
    ÅëÇÕ ¼÷ÁÖÀÎÀÚ(÷ÖùêâÖñ«ì×í­)
  • cloning host
    Ŭ·Î´× ¼÷ÁÖ(âÖñ«)
  • host
    ¼÷ÁÖ(âÖñ«)
  • host-controlled modification
    ¼÷ÁÖÁ¦¾î ¼ö½Ä(âÖñ«ð¤åÙáóãÞ)
  • host-controlled restriction
    ¼÷ÁÖÁ¦¾î Á¦ÇÑ(âÖñ«ð¤åÙð¤ùÚ)
  • host-guest system
    ÁÖ-°´(ñ«-ËÔ) ½Ã½ºÅÛ
  • host-induced modification
    ¼÷ÁÖÀ¯µµ ¼ö½Ä(âÖñ«ë¯ÓôáóãÞ)
  • host range
    ¼÷ÁÖ ¹üÀ§(âÖñ«ÛôêÌ)
  • host-range mutant
    ¼÷ÁÖ¹üÀ§ º¯ÀÌÁÖ(âÖñ«ÛôêÌܨì¶ñ»)
  • cell factor
    ¼¼Æ÷ÀÎÀÚ(á¬øàì×í­)
  • T cell growth factor
    T ¼¼Æ÷¼ºÀåÀÎÀÚ (á¬øàà÷íþì×í­)
  • absorption cell
    Èí¼ö¼Ò°ü (ýåâ¥á³Î·)
  • amplifier T cell
    Áõ½Ä T ¼¼Æ÷(ñòãÖ T á¬øà)
  • antigen presenting cell
    Ç׿øº¸À¯¼¼Æ÷(ù÷ê«ÜÁêóá¬øà)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • host
    ¼÷ÁÖ, ¼ö¿ëÀÚ, ÇÇÀ̽Äü
  • host computer
    ÁÖÄÄÇ»ÅÍ
  • attenuation factor
    °¨¾à¿ä¼Ò, °¨¼è¿äÀÎ
  • conversion factor
    º¯È¯ÀÎÀÚ
  • factor
    ÀÎÀÚ
  • predisposing factor
    ¼ÒÀÎ, Áúº´¼ÒÁú
  • Q factor
    Å¥ÀÎÀÚ
  • rheumatoid factor
    ·ù¸¶Æ¼½º¾çÀÎÀÚ
  • risk factor
    À§Çè¿äÀÎ
  • turbo factor
    Åͺ¸ÀÎÀÚ
  • acinar cell
    Æ÷»ó¼¼Æ÷
  • air cell
    ÇԱ⵿
  • alveolar cell carcinoma
    ÆóÆ÷¼¼Æ÷¾ÏÁ¾
  • basal cell carcinoma
    ±âÀú¼¼Æ÷¾ÏÁ¾
  • blast cell
    ¸ð¼¼Æ÷
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
CF calcaneal fibular [ligament]; calcium leucovorin; calf blood flow; calibration factor; cancer-free; ...
EF ectopic focus; edema factor; ejection fraction; elastic fibril; electric field; elongation factor; e...
PF pair feeding; peak flow; perfusion fluid; pericardial fluid; periosteal fibroblast; peritoneal fluid...
SF Sabin-Feldman [test]; safety factor; salt-free; scarlet fever; screen film; seminal fluid; serosal f...
MC mass casualties; mast cell; Master of Surgery [Lat. Magister Chirurgiae]; maximum concentration; Med...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
HCR Host cell reactivation
IHF Integration Host Factor
AGVHD Acute graft-versus-host disease
aGVHD Acute graft-vs.-host disease
cGVHD Chronic graft versus host disease
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • host
    ¼÷ÁÖ, °³Ã¼, ¼ö¿ëÀÚ, ÇÇÀ̽Äü
    1. ¼÷ÁÖ-´Ù¸¥ »ý¹°À» ±â»ý½ÃÄÑ, ¿µ¾çÀ» °ø±ÞÇÏ´Â µ¿¹° ¶Ç´Â ½Ä¹°. 2. ÇÇÀ̽Äü, ¼ö¿ëÀÚ-´Ù¸¥ »ý¹°·ÎºÎÅÍ ±â°ü ¶Ç´Â Á¶Á÷ÀÇ À̽ÄÀ» ¹Þ´Â ¼ö¿ëÀÚ.
  • host-parasitite relationship
    ¼÷ÁÖ-±â»ýüÀÇ »óÈ£ °ü°è
  • pneumonia,in immunocompromised host
    ¸é¿ª ±â´É ÀúÇÏ ¼÷ÁÖÀÇ
  • IGF-I : insulin like growth factor-IÀÇ ¾àÀÚ. ¼ºÀåÆÇÀÎ epiphyseal plate¿¡ ¿¬°ñ »ý¼ºÀ» Áõ°¡½ÃÄÑ »ÀÀÇ ¼ºÀåÀ» ÃËÁøÇÑ´Ù.

    IGF-II : insulin like growth factor-IIÀÇ ¾àÀÚ. ¸¹Àº Àå±â¿Í Á¶Á÷¿¡ ÀÛ¿ëÇÏ¿© ´Ü¹é ÇÕ¼º°ú DNA, RNAÀÇ ÇÕ¼ºÀ» Áõ°¡½ÃÄÑ ¼¼Æ÷ÀÇ ¼ö¿Í ¾çÀ» Áõ°¡

    Àν¶¸°¾ç ¼ºÀå ÀÎÀÚ °áÇÕ ´Ü¹éÁú
    insulinelike growth factor binding
  • single-factor versus multiple-factor analysis
    ´ÜÀÏ ¿ä¼Ò ºÐ¼® ´ë º¹ÇÕ ¿ä¼Ò ºÐ¼®
  • B cell growth factor
    B ¼¼Æ÷ ¼ºÀå ÀÎÀÚ, B ¼¼Æ÷ Áõ½Ä ÀÎÀÚ
    B ¼¼Æ÷°¡ ÇüÁú ¼¼Æ÷·Î ºÐÈ­ÇÏ´Â °úÁ¤Àº Å©°Ô 2´Ü°è·Î ³ª´©¾îÁø´Ù. Ç׿ø ÀÚ±ØÀ» ¹ÞÀº B ¼¼Æ÷´Â ¿ì¼± Áõ½ÄÇϰí, ±× ÈÄ¿¡ Ç×ü¸¦ »ý»êÇÏ¿© ºÐºñÇÏ´Â ÇüÁú ¼¼Æ÷·Î ºÐÈ­¸¦ ¿Ï¼öÇÑ´Ù. Ç׿ø ÀÚ±ØÀ» ¹ÞÀº B ¼¼Æ÷´Â ±× ÀÚÁ¦¸¸À¸·Î´Â Áõ½ÄÇÏÁö ¸øÇϰí T¼¼Æ÷ À¯·¡ÀÇ B ¼¼Æ÷ Áõ½Ä ÀÎÀÚ³ª Ž½Ä ¼¼Æ÷ À¯·¡ ÀÎÀÚ IL-1ÀÇ ÀÚ±ØÀÌ Ãß°¡µÇ¾î Áõ½ÄÀ» ½ÃÀÛÇÑ´Ù. B ¼¼Æ÷ Áõ½Ä ÀÎÀÚ´Â Á¤»óÀÇ T¼¼Æ÷¸¦
  • B cell stimulating factor 1
    B ¼¼Æ÷ ÃËÁø ÀÎÀÚ 1
    µ¿ÀǾî´Â Interleukin 4·Î ¾Ë·ÁÁø ´ç´Ü¹éÀ¸·Î¼­ T ¼¼Æ÷, ºñ¸¸¼¼Æ÷ µî¿¡¼­ »ý»êµÈ´Ù. À̰ÍÀº B ¼¼Æ÷¿¡ ´ëÇØ comitogenÀ¸·Î ÀÛ¿ëÇϴµ¥ ±× ¿µÇâÀº B ¼¼Æ÷ÀÇ ¼º¼÷µµ¿¡ µû¶ó ´Ù¸£´Ù.
  • stem cell factor
    °£ ¼¼Æ÷ ¿ä¼Ò
  • clear cell basal cell carcinoma
    Åõ¸í ¼¼Æ÷ ±âÀú¼¼Æ÷¾Ï
  • absorbed dose conversion factor
    Èí¼ö¼±·® º¯È¯ °è¼ö
  • accessory food factor
    ¿µ¾ç º¸Á¶ ÀÎÀÚ
    F.G Ho
  • air kerma calibration factor
    °ø±â Ä¿¸¶ ÃøÁ¤ °è¼ö, ´«±Ý ¸ÂÃã °è¼ö
  • alveolar dilution factor
    ÆóÆ÷ Èñ¼® ÀÎÀÚ
  • angiogenesis factor
    Ç÷°ü Çü¼º ÀÎÀÚ
    ½Å»ý Ç÷°ü Áõ½ÄÀ» À¯µµÇÏ´Â ¹°Áú·Î¼­, Á¾¾çÀ̳ª ¸Á¸· °°Àº ½ÅÁø´ë»ç·®ÀÌ Å« Á¶Á÷¿¡¼­ ¹ß°ßµÈ´Ù. ÀÌ ÀÎÀÚ´Â »óóÀÇ °¡ÀåÀÚ¸®³ª Ç¥¸é¿¡ ÀÖ´Â Àú»ê¼Ò »óÅÂÀÇ ´ë½Ä¼¼Æ÷¿¡¼­ ºÐºñµÇ¸ç, »óó Ä¡À¯ °úÁ¤¿¡¼­ Ç÷°ü ÀçÇü¼ºÀ» À¯µµÇÑ´Ù.
  • anisotropy factor
    ºñµî¹æ¼º °è¼ö
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
host cell A cell which has been infected by a virus is known as the host cell of that virus.
A cell which is used in lab techniques such as DNA cloning to receive, maintain, and allow the reproduction of recombinant DNA cloning vectors. The DNA introduced with the vector is replicated whenever the cell divides and the recombinant proteins encoded for by the plasmid are reproduced in large quantities.
(13 Nov 1997)
accidental host One that harbors an organism which usually does not infect it.
(05 Mar 2000)
amplifier host A host in which infectious agents multiply rapidly to high levels, providing an important source of infection for vectors in vector-borne diseases.
(05 Mar 2000)
parasite-host ecosystem Complex of all parasite species and individuals associated with a specific host.
Synonym: parasite-host ecosystem.
Origin: parasite + G. Koinos, common, together
(05 Mar 2000)
paratenic host An intermediate host in which no development of the parasite occurs, although its presence may be required as an essential link in the completion of the parasite's life cycle; e.g., the successive fish host's that carry the plerocercoid of Diphyllobothrium latum, the broad fish tapeworm, to larger food fish eventually eaten by man or other final host's.
Synonym: transport host.
(05 Mar 2000)
reservoir host The host of an infection in which the infectious agent multiplies and/or develops, and upon which the agent is dependent for survival in nature; the host essential for the maintenance of the infection during times when active transmission is not occurring.
(05 Mar 2000)
graft-versus-host disease <haematology> A common and serious, complication of bone marrow transplantation where there is a reaction of donated bone marrow against a patient's own tissue.
When donor lymphocytes or a graft containing lymphocytes that are immunologically competent are given to a patient that has low immunological competence, an incompatibility reaction can result. This is due to antibodies from the donor against antigens in the host. This is due to mismatch of MHC Class I antigens and can produce lymphocyte clones that will react by a variety of processes against the host and cause damage.
The clinical condition can be fatal and is due to the donor's immune cells recognising the host cells as foreign.
The clinical entity characterised by anorexia, diarrhoea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the graft-versus-host reaction. It can occur in either chronic or acute forms and is treatable by immunosuppressive drugs.
Seen most commonly following bone marrow transplantation, acute disease is seen after 5-40 days and chronic disease weeks to months after transplantation, affecting, principally, the gastrointestinal tract, liver, and skin.
Radiological appearances of the gastrointestinal tract include; thickened wall, mucosal folds thickened or effaced, increased secretions most likely to be rapid transit of GI tract, mass most likely to be focal oedema, fibrosis, hallmark: diffuse, uniform thickening of small bowel.
Synonym: GVH disease.
Acronym: GVHD
(20 Sep 2002)
graft-versus-host reaction <haematology> A common and serious, complication of bone marrow transplantation where there is a reaction of donated bone marrow against a patient's own tissue.
When donor lymphocytes or a graft containing lymphocytes that are immunologically competent are given to a patient that has low immunological competence, an incompatibility reaction can result. This is due to antibodies from the donor against antigens in the host. This is due to mismatch of MHC Class I antigens and can produce lymphocyte clones that will react by a variety of processes against the host and cause damage.
The clinical condition can be fatal and is due to the donor's immune cells recognising the host cells as foreign.
The clinical entity characterised by anorexia, diarrhoea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the graft-versus-host reaction. It can occur in either chronic or acute forms and is treatable by immunosuppressive drugs.
Seen most commonly following bone marrow transplantation, acute disease is seen after 5-40 days and chronic disease weeks to months after transplantation, affecting, principally, the gastrointestinal tract, liver, and skin.
Radiological appearances of the gastrointestinal tract include; thickened wall, mucosal folds thickened or effaced, increased secretions most likely to be rapid transit of GI tract, mass most likely to be focal oedema, fibrosis, hallmark: diffuse, uniform thickening of small bowel.
Synonym: GVH disease.
Acronym: GVHD
(20 Sep 2002)
graft-versus-host response <haematology> A common and serious, complication of bone marrow transplantation where there is a reaction of donated bone marrow against a patient's own tissue.
When donor lymphocytes or a graft containing lymphocytes that are immunologically competent are given to a patient that has low immunological competence, an incompatibility reaction can result. This is due to antibodies from the donor against antigens in the host. This is due to mismatch of MHC Class I antigens and can produce lymphocyte clones that will react by a variety of processes against the host and cause damage.
The clinical condition can be fatal and is due to the donor's immune cells recognising the host cells as foreign.
The clinical entity characterised by anorexia, diarrhoea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the graft-versus-host reaction. It can occur in either chronic or acute forms and is treatable by immunosuppressive drugs.
Seen most commonly following bone marrow transplantation, acute disease is seen after 5-40 days and chronic disease weeks to months after transplantation, affecting, principally, the gastrointestinal tract, liver, and skin.
Radiological appearances of the gastrointestinal tract include; thickened wall, mucosal folds thickened or effaced, increased secretions most likely to be rapid transit of GI tract, mass most likely to be focal oedema, fibrosis, hallmark: diffuse, uniform thickening of small bowel.
Synonym: GVH disease.
Acronym: GVHD
(20 Sep 2002)
cutaneous graft versus host reaction An acute erythematous maculopapular reaction with bulla formation in the most severe cases; chronic changes may resemble lichen planus or scleroderma.
(05 Mar 2000)
secondary host <epidemiology> See vector.
(05 Dec 1998)
host An organism that is infected with or is fed upon by a parasitic or pathogenic organism (for example, a virus, nematode, fungus). The term can also be applied, loosely, to a plant supporting an epiphyte.
(09 Oct 1997)
host-parasite relations The interactions between two organisms, one of which lives at the expense of the other.
(12 Dec 1998)
host range The range of host species or cell types which a particular virus, bacteria, or parasite is able to infect or parasitise.
(09 Oct 1997)
host range mutant A mutant of phage or animal virus that grows normally in one of its host cells, but has lost the ability to grow in cells of a second host type.
(18 Nov 1997)
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 1 ÆäÀÌÁö: 1
  • Host Cell Factor C1 - »õâ A cellular transcriptional coactivator that was originally identified by its requirement for the stable assembly IMMEDIATE-EARLY PROTEINS of the HERPES SIMPLEX VIRUS. It is a nuclear protein that is a transcriptional coactivator for a number of transcription factors including VP16 PROTEIN; GA-BINDING PROTEIN; EARLY GROWTH RESPONSE PROTEIN 2; and E2F4 TRANSCRIPTION FACTOR. It also interacts with and stabilizes HERPES SIMPLEX VIRUS PROTEIN VMW65 and helps regulate GENETIC TRANSCRIPTION of IMMEDIATE-EARLY GENES in HERPES SIMPLEX VIRUS.
    Synonyms : C1 Host Cell Factor, Cell Proliferation Factor HCF
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • a host of
    -ÀÌ ¸¹Àº
  • host
    ÁÖÀÎ; ±ºÁß; ¹«¸®
  • definitive host
    (»ý)Á¾°á(°íÀ¯)¼÷ÁÖ
  • host
    (¼Õ´Ô¿¡ ´ëÇÏ¿©) ÁÖÀÎ;(¿©°üÀÇ) (³²ÀÚ) ÁÖÀÎ;(±â»ý »ý¹°ÀÇ) ¼÷ÁÖ;reckon(count) without one's ~ Á¦¸Ú´ë·Î Ä¡ºÎ(ÆÇ´Ü)ÇÏ´Ù
  • host
    ¸¹Àº ¶¼;´Ù¼ö;±º¼¼;heavenly ~s;~(s) of heaven ÇÏ´ÃÀÇ º°;õ»çÀÇ ¶¼
  • host city
    (°æ±â µîÀÇ)°³ÃÖ µµ½Ã
  • host computer
    (´Ü¸»±â,¸¶ÀÌÅ©·Î ÄÄÇ»Å͸¦ °Å´À¸°)È£½ºÆ® ÄÄÇ»ÅÍ;´ë¿ë·® ÄÄÇ»ÅÍ
  • host plant
    ±âÁÖ ½Ä¹°
  • intermediate host
    Áß°£¼÷ÁÖ(±â»ýÃæÀÇ À¯»ý±âÀÇ ¼÷ÁÖ)
  • factor
    ¿ä¼Ò,¿äÀÎ
  • F factor
    FÀÎÀÚ;¿°¼ºÀÎÀÚ
  • R factor
    R ÀÎÀÚ(¼¼±ÕÀÇ ¾àÁ¦ ³»¼º ÀÎÀÚ)
  • Rh factor
    ¸®¼­½º ÀÎÀÚ(ÀûÇ÷±¸ ¼Ó¿¡ ÀÖ´Â ÀÀÇ÷¼Ò)
  • Rhesus factor(antigen)
    =RH FACTOR
  • coal-factor
    ¼®Åº Áß°³ »óÀÎ(µµ¸Å »óÀÎ)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á